SHENZHEN WORLD EXPO TRADING GROUP LIMITED – Trademark Portfolio

Entity Type: 99

SHENZHEN WORLD EXPO TRADING GROUP LIMITED holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include JOMANI. The owner is based in HONG KONG.

UNIT D18, 3/F, WONG KING INDUSTRIAL BUILDING

NO.2-4 TAI YAU STREET, SAN PO KONG,

HONG KONG 999077 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

JOMANI
JOMANI
Registered 2020

Trademark Classifications

SHENZHEN WORLD EXPO TRADING GROUP LIMITED's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does SHENZHEN WORLD EXPO TRADING GROUP LIMITED have?

SHENZHEN WORLD EXPO TRADING GROUP LIMITED has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does SHENZHEN WORLD EXPO TRADING GROUP LIMITED file in?

SHENZHEN WORLD EXPO TRADING GROUP LIMITED files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are SHENZHEN WORLD EXPO TRADING GROUP LIMITED's most well-known trademarks?

SHENZHEN WORLD EXPO TRADING GROUP LIMITED's registered trademark portfolio includes well-known marks such as JOMANI. These are among 1 currently registered trademark in the portfolio.

What is SHENZHEN WORLD EXPO TRADING GROUP LIMITED's trademark registration success rate?

SHENZHEN WORLD EXPO TRADING GROUP LIMITED has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.